Delivery Order SPE2DE21D7010-SPE2D626F42C8

Nuvasive, Inc., a San Diego-based medical device manufacturer and subsidiary of Transplant Technology Inc.'s Bone Bank Allografts division, was awarded a $23,948.58 delivery order for OSTEOCEL PRO on December 18, 2025, with an ultimate completion date of January 9, 2026. This fixed-price contract with economic price adjustment mechanisms was funded by the Defense Logistics Agency Medical Supply Chain, a Defense Department entity responsible for procuring medical supplies and equipment for Department of Defense and Department of Veterans Affairs healthcare facilities. The award was issued without set-aside designation, reflecting Nuvasive's competitive standing in open market procurements. Performance will be conducted at Nuvasive's San Diego, California facility, with the product delivery expected within weeks of the award date, consistent with the urgent medical supply needs of the military health system.

This delivery order is issued against Nuvasive's broader indefinite delivery infrastructure, including the company's participation in an $8 million Blanket Purchase Agreement with the Defense Health Agency structured as an Indefinite Delivery/Indefinite Quantity contract vehicle effective through March 2027. OSTEOCEL PRO represents part of Nuvasive's comprehensive portfolio of spinal fusion devices, bone graft materials, and surgical instrumentation that support advanced orthopedic and neurosurgical procedures across federal healthcare facilities. Through this contracting mechanism and related DLA Medical Supply Chain vehicles, Nuvasive has established itself as a critical supplier of specialized spinal and bone graft technologies that directly support the operational readiness and medical mission effectiveness of the federal healthcare enterprise.